

At Regeneron,  
everything starts  
with **science**



**PharmD**  
BIOLOGICS PROGRAM

**REGENERON**

# CONTENTS

<b>4</b>	About Regeneron
<b>5-12</b>	PharmD Biologics Program
<b>13</b>	PharmD Biologics Program Alumni
<b>14</b>	Want To Be Part of The PBP?
<b>15-16</b>	Program Leadership
<b>17</b>	Q&A
<b>18</b>	Clinical Product Candidates
<b>19</b>	Regeneron By The Numbers
<b>20</b>	Technology and Marketed Products
<b>21</b>	Leonard Schleifer, MD, PhD and George Yancopoulos, MD, PhD
<b>22</b>	Awards
<b>23</b>	About Our Location



“The **Regeneron Way** defines the principles governing our daily work and is evident in the **cutting-edge science, collaborative team dynamics, and inspiring workplace culture.**”

Michelle Li, PharmD  
Rutgers University

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

## ABOUT THE COMPANY

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for more than 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to 9 FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.



## THE REGENERON WAY

### › Lead With Science

Science drives our business and passion drives our science. Whether you're doing science, supporting science or delivering science. It's what we do.

### › Take On Big Ideas

We take the long view and tackle the big ideas, the unsolvable problems and the bottlenecks that get in the way. We pursue ideas with passion and courage, to make a real difference.

### › Make It Happen

It may not always be easy, but we figure it out and get it done. We have little appetite for unnecessary bureaucracy that can get in the way of innovation or quality.

### › Be Great Together

While others talk about teamwork, we actually do it. When you work with smart, fun people, you bring out the best in each other and can do the extraordinary.

### › Do What's Right

We do well by doing good. We act with integrity and pride ourselves on doing the right thing – by each other, our communities, our patients and the world around us.



# PHARMD BIOLOGICS PROGRAM



The PharmD Biologics Program (PBP) is an intensive, rotational, interdisciplinary program for graduating PharmD candidates. The objective for the PBP is to provide training by Regeneron subject matter experts and hands-on experience in a variety of global development roles. The PBP is for highly motivated individuals seeking to build a career in the biopharmaceutical industry with a foundation in Clinical Sciences, Safety Sciences, Development Operations & Program Management, and/or Regulatory Affairs.

## OBJECTIVES

PharmD Associates will:

- » Gain knowledge of biopharmaceutical development in a variety of clinical development-related roles
- » Develop a balanced foundation of skills through hands-on experience in industry areas such as clinical development and regulatory affairs
- » Cultivate technical and non-technical skills through diverse cross-functional experiences, ongoing mentorship, and targeted training
- » Engage in interdisciplinary professional development sessions to maximize the learning and overall experience at Regeneron

## WHO IS THE IDEAL PBP CANDIDATE?

The ideal applicant is flexible, intellectually curious, hard-working, and passionate about science and continuous learning.



The candidate graduated from an accredited pharmacy program. These individuals have a high academic standing preferably with some research experience. They have strong analytical, communication, and organizational skills and are adept at leadership and team roles.

This unique program provides participants with the foundation for multiple potential roles within Global Development. Throughout the program, participants will cultivate technical and non-technical skills through diverse cross-functional experiences, ongoing mentorship, and targeted training. Each assignment in this 2-year development program will expose candidates to critical issues and decision-making processes to gain broad experience across several clinical/scientific research areas. The selected program participants will acquire high level knowledge of the business and department operations, as well as gain hands-on work experience in a variety of areas.



# PROGRAM STRUCTURE OVERVIEW

24-months in one of these functional areas:



# FUNCTIONAL AREAS

## Track 1 | Development Operations & Program Management

In Development Operations, the Associate will focus on Clinical Operations and Program Management supporting and owning key activities across clinical trials and strategic programs in the Development Portfolio.

### In Clinical Trial Management, the Associate will support:

- Key activities during the clinical trial start-up, maintenance, and close out
- Program/Study Strategic Feasibility and Country and Site selection
- Site initiation visits (including presentations), site monitoring visits, patient enrollment planning and oversight
- Review clinical study budget and timelines, CRO and vendor management and interact cross-functionally with various internal team members and external clinical sites and vendors

### In Program Management, the Associate will support:

- Integrated drug development planning and execution from early development through BLA submission
- Budget, timeline, and project plan development and management
- Participation in and facilitation of governance meetings including Global Clinical Sub-Team, Strategic Program Team, Development Program Reviews, Protocol Review Committee
- Scenario planning and risk mitigation



**Current First Year PharmD Associate**

**DAGMARA KUTRZUBA, PHARM D**

University of Illinois Chicago

Dagmara is currently working in Clinical Trial Management supporting early development and Phase 2 oncology studies.

“Regeneron is a company driven by science whose goal is to improve therapeutic outcomes for patients. The PharmD Biologics Training Program allows its Associates to work collaboratively to gain exposure in several functions and therapeutic areas within the biopharmaceutical industry. The hands-on environment at Regeneron empowers its Associates to shape their learning experience and professional growth.”



**Current Second Year PharmD Associate**

**ELIZABETH LINDEMANN, PHARM D**

University of the Pacific

Elizabeth is currently working in Global Clinical Development on several Phase 1 and 2 rare disease studies.

“Regeneron is a company with a clear mission and strong culture that prioritizes science and patients. This program challenges its associates to take action, work collaboratively, and use science to bring the best medicines to patients while also deepening their understanding of the drug development process. Associates will explore all facets of the pharmaceutical industry from the perspective of a cutting-edge biotechnology company and gain relevant experiences to build a lifelong career.”



# FUNCTIONAL AREAS

## Track 2 | Clinical Sciences

In Clinical Sciences, the Associate will participate in activities throughout the lifetime of a drug development program from supporting the development of pre-IND/IND documents through regulatory submissions. The Clinical Scientist Associate will play an instrumental role through all phases of clinical development to bring life-changing medicines to patients. Studies supported may include translational research, clinical experimental sciences, early/late phase clinical trials, and post-marketing requirements.

### In Clinical Sciences, the Associate will:

- Participate in medical monitoring by reviewing data inputted from site and raising medical queries
- Contribute to the development of clinical study designs and protocol writing
- Develop key documents such as expanded synopses, protocol amendments, investigator brochures, safety reports, and monitoring plans
- Design case report forms for studies and participate in user acceptance testing for databases
- Participate in and facilitate key meetings with sites such as those regarding dose escalation decisions
- Train internal team members and site on study protocol
- Become familiar with regulatory agency guidances for study design of relevant trial phases, therapeutic areas, and drug technology



**Current First Year PharmD Associate**

**JANAKI VEKARIA, PHARM D**

Rutgers University

Janaki is currently working in Early Clinical Development where she supports rare disease and COVID-19 studies.

“Regeneron is a company that truly uses the power of science to drive the development of life-changing medications. Through this approach, it has become the forefront of biotechnology and changed the landscape for many diseases with unmet needs. This program allows for its Associates to delve into the biologics drug development process and experience the rigor of Regeneron’s challenging and innovative trials.”

# FUNCTIONAL AREAS

## Track 3 | Regulatory Strategy

In Regulatory Strategy, the Associate will support and provide project management for the operations governing pharmaceutical drug development to all aspects of Regeneron's quality, preclinical and clinical drug development programs, policies, and procedures meeting the necessary state of compliance relative to all regulatory commitments.

### In Regulatory Strategy, the Associate will:

- Participate in the development of regulatory strategies in collaboration with the development teams by conducting research and review of guidelines, regulatory precedence, and competitive intelligence
- Assist in managing the timelines, preparation, compilation, review, organization, and submission of regulatory deliverables including INDs, CTAs, BLAs, IND amendments, and BLA supplements in accordance with title 21 CFR and all FDA and ICH guidelines
- Support the drafting and review of regulatory documents, including briefing materials and labeling documents
- Manage overall completeness of scheduled submissions and coordinate with Regulatory Operations on submission timing and document status
- Participate in cross-functional departmental team projects and product development activities/meetings



**Current First Year PharmD Associate**

**MICHELLE LI, PHARM D**

Rutgers University

Michelle is currently working in Regulatory Submission Project Management supporting General Medicine programs.

“Regeneron is a company that is characterized by passionate people who work collaboratively to bring innovative therapies to patients. This program provides the opportunity for Associates to learn and grow in a fast-paced environment with the support of senior leaders in various functional areas. Associates are empowered to be curious, think critically, and make impactful contributions in the drug development process.”



**Current Second Year PharmD Associate**

**JERRY SICALO, PHARM D**

University of Colorado

Jerry is currently working in Global Regulatory Strategy and is supporting the Immunology & Inflammation portfolio.

“Regeneron is a company that is driven by science and individuals who are passionate about making meaningful change. The program provides a unique opportunity for Associates to gain fundamental understanding of the clinical development process in a quick-learning and supportive environment while also allowing for focus on areas of special interest.”

# FUNCTIONAL AREAS

## Track 4 | Regulatory Labeling and Advertising/Promotion

In Regulatory Labeling and Advertising/Promotion the Associate will gain knowledge on the role of Labeling throughout a drug's life cycle, learn about the role of Ad Promo in the commercialization of drug products, and collaborate cross functionally with key stakeholders.

### In Regulatory Labeling Strategy, the Associate will:

- Contribute to the development of healthcare provider (HCP) and patient labeling documents for regulatory submissions, including participating in Labeling Working Groups and obtaining management approval of labeling documents
- Manage the Labeling process throughout the product life cycle, prepare submission-ready labeling documents and support preparation of responses to Health Authorities during labeling negotiations
- Contribute to the development of labeling strategies through interpretation of regulations and guidelines

### In Advertising & Promotion, the Associate will:

- Develop knowledge and skills to interpret FDA regulations and guidances to ensure promotional communication for HCPs and consumers is truthful and not misleading, and appropriately advise teams on associated regulatory risks
- Assist in FDA - Office of Prescription Drug Promotion (OPDP) interactions for assigned company products and maintain effective working relationship with FDA OPDP reviewers
- Monitor the external environment on evolving regulatory landscape related to product and disease state communications to strategically advise internal product and cross-functional teams



**Current First Year PharmD Associate**

**TOLULOPE OMISAKIN, PHARM D**

St. John's University

Tolulope is currently working in Regulatory Labeling Strategy supporting the Immunology and Inflammation Portfolio.

“Regeneron is a company that inspires you to bring your best to the table every day. As Associates, we are challenged with meaningful work in a fast-paced learning environment under the guidance of passionate mentors. This Program takes the foundation of knowledge from your didactic training and allows you to apply it to cutting-edge science in the drug development process.”

# FUNCTIONAL AREAS

## Track 5 | Safety Sciences

In Safety Sciences, the Associate will gain a working knowledge of various disciplines that enable the continuous assessment of the benefit-risk of Regeneron products throughout their lifecycle, from early clinical development through market authorization and postmarketing surveillance, with a focus on signal detection and management. This includes gaining an understanding of safety data collection, evaluation, and reporting, establishing the framework for signal detection and management activities. There will be close collaboration with other disciplines within Global Development to provide a well-rounded perspective on how safety contributes to successful drug development and ensures safe use of Regeneron's products.

### In Safety Sciences, the Associate will:

- Understand Individual Case Safety Report (ICSR) data collection, evaluation, and reporting, including a working knowledge of safety database and tools
- Support preparation of safety aggregate reports for development and marketed products
- Understand business support functions for Global Patient Safety, including quality standards and system, compliance monitoring, regulatory intelligence monitoring, and safety data exchange agreements
- Gain an understanding of how pharmacoepidemiology data plays a key role in the overall safety assessment through participation in the planning and execution of a pharmacoepidemiology project
- Participate and support signal detection activities, include data review, signal evaluation report preparation, drafting risk management plans, response to regulatory inquiries, and preparation of other safety submissions
- Organize, support, and participate in Safety Management Team (SMT) meetings



# HOW HAS YOUR **EXPERIENCE** IN THE PHARMD PROGRAM **PREPARED YOU** FOR YOUR ROLES?



“Working across several functions and therapeutic areas as an Associate has not only supported my professional development through well-rounded hands-on experiences, it has also enabled me to build relationships with and learn from talented team members and mentors.”

**JENNIFER LIANG, PHARM D**  
Manager, Medical Affairs



“The ability to train within different functional areas during the PharmD Biologics Program prepared me as a Clinical Scientist to think and plan using parallel viewpoints and thought processes for the strategy, design and, implementation of early clinical development programs.”

**ANDREW KORDAHI, PHARM D**  
Manager, Early Clinical Development



“Regeneron is a company that embraces science and whose number one goal is to help patients. The PharmD Biologics Program offers a unique rotational experience that allows the Associate to experience all parts of the biologics drug development process. The ability to work in different functional areas and stages of development has allowed me to effectively transition to a Global Regulatory Liaison role directly out of this program.”

**BRIAN SNOW, PHARM D**  
Manager, Regulatory Affairs



“The program here at Regeneron has a strong emphasis on mentorship and professional growth. While learning how core functional areas in the pharmaceutical industry work together to support drug development I was constantly encouraged to expand and refine the skills needed to be a successful member of the team.”

**RYAN PENNINGTON, PHARM D**  
Manager, Regulatory Affairs Labeling

# Want to be part of the PBP?



## APPLY AT [CAREERS.REGENERON.COM](https://careers.regeneron.com) AND SEARCH PHARMD BIOLOGICS PROGRAM

- » Application must include CV and cover letter indicating track(s) of interest
- » Final interviews will be conducted virtually and in person at ASHP Midyear Conference
- » **Application deadline: October 21st**

## IF YOU HAVE QUESTIONS, PLEASE CONTACT:

Bailie Saltzman  
HR Contact - Sr Talent Acquisition Specialist  
[pharmdbp@regeneron.com](mailto:pharmdbp@regeneron.com)



Application opens at  
[careers.regeneron.com](https://careers.regeneron.com)  
on October 1st



Applications are reviewed  
on a rolling basis



Online application portal  
closes October 21st



Interviews will be  
scheduled with  
candidates directly

# PROGRAM LEADERSHIP

## EXECUTIVE PROGRAM SPONSORS



**BARI KOWAL**  
Senior Vice President, Development  
Operations and Portfolio Management



**MARY ALICE RAUDENBUSH**  
Vice President, CMC, Regulatory Affairs

## PROGRAM ADVISORS AND MENTORS



“I’m excited to be a program mentor where numerous opportunities exist for PharmD graduates to explore several departments. Our ‘science first’ culture at Regeneron, which fosters curiosity, collaboration, and exploration, is embedded into the program, giving us opportunities to continually learn and grow at the company.”

**MIRIAM KORE, PHARM D**  
Senior Director, Clinical Trial Management



“The Biologics Program at Regeneron is a two-way avenue, where PharmD graduates have a unique opportunity to learn and contribute to the cutting-edge science and drug development that is performed across several departments, and at the same time it allows Regeneron Associates to advance their people managing and mentoring skills.”

**EDUARDO FORLEO NETO, MD**  
Executive Director, Clinical Sciences



“Our program is designed to develop Associates into strong leaders in their chosen careers by providing mentorship and guidance, integrating them into the development teams, and providing opportunities to make meaningful contributions to achieve program goals.”

**YUNJI KIM, PHARM D**  
Senior Director, Regulatory Affairs

The program advisors are available to help navigate your experience, help you connect with resources within the company, and provide feedback to support your continued growth at Regeneron.

## PROGRAM ADVISORS AND MENTORS



“It is truly energizing to work at Regeneron where you are surrounded by exceptionally talented individuals in a highly collaborative environment, all working together to progress great science and improve patient lives. Our PharmD Associates have a unique opportunity to not only learn through observing and shadowing, but also to actually manage projects on their own within a short time frame and feel the impact of their contributions, as they learn. It is extremely rewarding to be a part of such a program.”

### PEARL RAWSON, PHARM D

Executive Director, Regulatory Labeling & Advertising/Promotion



“The Biologics Program at Regeneron provides PharmD Associates the opportunity to gain a broad experience across multiple development functions, providing a foundation to those beginning their biopharmaceutical careers. We strive to provide fellows with the opportunity to learn and explore and value them as integral members of our project teams.”

### STEPHANIE BIEDERMANN

Senior Director, Development Program Management



“I'm very excited to be a board member and a mentor for this program to share my passion for drug development and mentoring highly engaged and committed individuals like yourself to achieve your goals to be the next generation leaders. This program will offer you an opportunity to explore and find your passion for the area of your interest and to continually learn and grow in The Regeneron Way where we Lead With Science, Take On Big Ideas, Make It Happen, Be Great Together, and Do What's Right. At Regeneron, it's all about the PATIENT!”

### YAMINI PATEL, PH D

Executive Director, Global Program Head



“For graduates keenly interested in pursuing a career with a science-driven biopharmaceutical company, the Regeneron PharmD Biologics Program opens the door to an exceptional opportunity for exploration and education. Through diverse “hands on” learning and cross-functional collaboration experiences, the program enables Associates to cultivate a deep understanding of drug development, hone an invaluable skillset and make meaningful contributions along the way. Regeneron's longstanding culture of fostering curiosity and encouraging innovation further serves to enrich the professional development of tomorrow's motivated and aspiring leaders.”

### KRISTEN SCHEBLE, PHARM D

Senior Director, Medical Affairs



“The Biologics Program at Regeneron provides the opportunity for PharmD graduates to get the best-in-class training at one of the most scientifically-minded biotech organizations. Regeneron is deeply rooted in its belief of “doing well by doing good”, reflected in every aspect of our work. There's wide recognition that our people are our most important asset, and developing talent from within enables our mission of advancement in science and ultimately benefiting patients. I am very proud to be part of this important program!”

### TINA HO, PHARM D

Executive Director, Global Patient Safety



# Q&A

## 1. What is the difference between a fellowship and our PharmD program?

Our program has no university affiliation and the expectation from Associates is that they are fully active members of the team.

## 2. Do you choose your therapeutic area or is it assigned to you?

Designation of therapeutic area is decided based on a combination of personal interests, business need, and availability of team members to mentor new Associates.

## 3. When will we hear back after we submit our application?

This is a rolling submission. Applicants are strongly encouraged to submit application materials as soon as possible to request an interview.

## 4. To whom should the cover letter and other application requirements be addressed?

Please address your letter of intent to:

**PharmD Biologics Program**  
**Regeneron Pharmaceuticals**  
**777 Old Saw Mill River Rd**  
**Tarrytown, NY 10591**



# CLINICAL PRODUCT CANDIDATES

## PHASE 1

### ALN-APP <sup>3</sup>

APP RNAi Therapeutic  
Early-onset Alzheimer's disease

### ALN-HSD <sup>3</sup>

HSD17B13 RNAi Therapeutic  
Nonalcoholic steatohepatitis

### FIANLIMAB

LAG-3 Antibody | Solid tumors, advanced hematologic malignancies

### NTLA-2001 <sup>1</sup>

CRISPR/Cas9  
Transthyretin (ATTR) amyloidosis

### ODRONEXTAMAB

CD20 X CD3 Antibody  
Certain B-cell malignancies

### UBAMATAMAB (REGN4018)

MUC16 X CD3 Antibody  
Platinum-resistant ovarian cancer

### REGN4336

PSMA X CD3 Antibody  
Prostate cancer

### REGN5093

MET X MET Antibody  
MET-altered advanced non-small cell lung cancer (NSCLC)

### REGN5093-M114

MET X MET Antibody  
MET overexpressing advanced cancer

In collaboration with:

<sup>1</sup> Sanofi | <sup>2</sup> Teva and Mitsubishi Tanabe | <sup>3</sup> Bayer | <sup>4</sup> Intellia | <sup>5</sup> Alnylam | <sup>6</sup> Roche

### REGN5381/REGN9035

Agonist Antibody to NPR1/Reversal Agent to REGN5381 | Reversal agent in healthy volunteers

### REGN5458

BCMA X CD3 Antibody  
Multiple myeloma

### REGN5459

BCMA X CD3 Antibody  
Transplant desensitization in patients with chronic kidney disease

### REGN5668

MUC16 x CD28 Antibody  
Platinum-resistant ovarian cancer

### REGN5678

PSMA X CD28 Antibody  
Prostate cancer

### REGN6569

G1TR Antibody | Solid tumors

### REGN7075

EGFR x CD28 Antibody  
Solid tumors

### REGN7257

IL-2Rg Antibody  
Aplastic anemia

### REGN9933

Factor XI Antibody  
Thrombosis

### Next Generation Covid-19 Antibodies

Antibodies to SARS-CoV-2 Variants | Healthy volunteers

## PHASE 2

### CEMDISIRAN <sup>3</sup>

C5 siRNA Therapeutic  
Immunoglobulin A nephropathy

### CEMIPLIMAB

PD-1 Antibody  
Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC, second-line cervical cancer ISA101b combination

### DUPILUMAB <sup>1</sup>

IL-4R Antibody  
Grass allergy

### GARETOSMAB

Activin-A Antibody  
Fibrodysplasia ossificans progressive (FOP)

### ODRONEXTAMAB

CD20 X CD3 Antibody  
B-cell non-Hodgkin lymphoma

### POZELIMAB

C5 Antibody  
CD55-deficient protein-losing enteropathy

### MIBAVADEMAB

(REGN4461)  
LEPR Agonist Antibody  
Generalized lipodystrophy, partial lipodystrophy

### REGN5381/REGN9035

Agonist antibody to NPR1/reversal agent to REGN5381  
Heart failure

### REGN5458

BCMA X CD3 Antibody  
Multiple myeloma

### SARILUMAB <sup>1</sup>

IL-6R Antibody  
Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

### VIDUTOLIMOD

TLR9 immune activator  
CSCC and Merkel cell carcinoma

## PHASE 3

### AFLIBERCEPT <sup>3</sup>

VEGF-Trap  
Retinopathy of prematurity (ROP)

### AFLIBERCEPT 8 MG <sup>2</sup>

VEGF-Trap  
Wet age-related macular degeneration (AMD), diabetic macular edema (DME)

### ALIROCUMAB

PCSK9 Antibody  
Heterozygous familial hypercholesterolemia (HeFH) in pediatrics

### CEMIPLIMAB

PD-1 Antibody  
First-line non-small cell lung cancer (NSCLC) chemo combination, second-line cervical cancer, adjuvant CSCC

### DUPILUMAB <sup>1</sup>

IL-4R Antibody  
Chronic obstructive pulmonary disease (COPD); bullous pemphigoid; prurigo nodularis; chronic spontaneous urticaria; allergic bronchopulmonary aspergillosis; chronic inducible urticaria - cold; chronic rhinosinusitis without nasal polyposis; allergic fungal rhinosinusitis; chronic pruritis of unknown origin

### FASINUMAB <sup>2</sup>

NGF Antibody  
Osteoarthritis of the knee or hip

### FIANLIMAB

LAG-3 Antibody  
First-line metastatic melanoma

### ITEPEKIMAB <sup>1</sup>

IL-33 Antibody  
COPD

### POZELIMAB +

CEMDISIRAN <sup>3</sup>  
CD5 Antibody + C5 siRNA Therapeutic  
Myasthenia gravis, paroxysmal nocturnal hemoglobinuria

### REGN5713-5714-5715

Bet v 1 Multi-Antibody Therapy  
Birch allergy

### REGN1908-1909

Fel d 1 Multi-Antibody Therapy  
Cat allergy

■ Ophthalmology ■ Infectious Diseases ■ Immunology & Inflammatory Diseases ■ Oncology ■ Cardiovascular/Metabolic Diseases ■ Hematology ■ General Medicine ■ Rare Diseases ■ Pain

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases.

The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

# REGENERON BY THE NUMBERS

9 

FDA-approved medicines

~100%

nearly all drug candidates invented and developed in-house

30+ 

investigational medicines in clinical development across multiple therapeutic areas

242

peer-reviewed publications in 2021 

6 

consecutive years in *Forbes'* World's Most Innovative Companies

10K+ 

Regeneron employees worldwide

#1 

ranking in the *Science* Top Employer Survey for six of the past eleven years

12K

employee volunteer hours during 2021 *Day for Doing Good*

~2M 

exomes sequenced to date by the Regeneron Genetics Center®

# TECHNOLOGY

Our core capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process. Collectively, these technologies represent some of the most valuable biotechnologies ever created, and aid our efforts to continuously accelerate the average timeline from discovery to drug approval — ultimately allowing us to help more patients around the world, faster. We will continue to raise the bar for R&D excellence and productivity in the biotech industry.



## FDA-APPROVED & MARKETED MEDICINES\*

- 4** Arcalyst® (rilonacept) Injection for Subcutaneous Use
- 1** DUPIXENT® (dupilumab) Injection 100mg · 200mg · 300mg
- 5** Evkeeza® (evinacumab-dgnb) Injection
- 2** EYLEA® (aflibercept) Injector
- 1** Inmazole™ (atoltivimab, maftivimab, and odesivimab-ebgn)
- 1** KEVZARA® (sarilumab) injection 150 mg | 200 mg
- 1** LIBTAYO® (cemiplimab-rwlc) Injection 350 mg
- 1** Praluent® (alirocumab) Injection
- 3** ZALTRAP® (ziv-aflibercept)

**1** Dupixent is marketed jointly with Sanofi in the U.S. and in certain countries outside of the U.S. Kevzara is marketed jointly with Sanofi in the U.S. and by Sanofi outside of the U.S. Praluent is marketed by Sanofi outside of the U.S. | **2** EYLEA is marketed by Bayer outside of the U.S. | **3** Zaltrap was jointly developed by Sanofi and Regeneron and is marketed by Sanofi. | **4** Arcalyst was developed by Regeneron and is marketed by Kiniksa Pharmaceuticals | **5** Evkeeza is marketed by Ultragenyx outside of the U.S.



Regeneron has become one of the great science-driven companies of our generation, with nine approved treatments, an entirely homegrown pipeline and the best technologies in the business. We got here by following the science and trusting our people. But at Regeneron, we're never done. Our goal is to continue pushing the boundaries of science, to the extent that we aren't even able to imagine the breakthroughs and cures we will be known for in ten or twenty years. It's an incredible time to be at Regeneron, as we stand on the edge of an unprecedented future.

**GEORGE D. YANCOPOULOS, MD, PHD**  
Founding Scientist, President & Chief Scientific Officer

# AWARDS

Newsweek: America's Most Responsible Companies, 2022

Fortune's Best Workplaces in New York, 2022

Civic 50: Most Community-Minded Companies in the Nation, 2022

Forbes: World's Top Female Friendly Companies, 2021

Forbes: Best Employer – New York State, 2021

Fast Company: Best Workplaces for Innovators, 2021

Great Place To Work: Fortune 100 Best Companies to Work For, 2021



Fast Company: World Changing Ideas (Pandemic Response), 2021

IDEA Pharma: Pharmaceutical Invention Index, 2021

Science: Top Employer, 2021

Forbes: JUST Companies, 2021

Dow Jones Sustainability World Index, 2021


Dow Jones Sustainability North America Index, 2021

Shingo Institute: The Shingo Prize, 2019

# ABOUT OUR LOCATION

The PharmD Biologics Program is located in Tarrytown, NY. Tarrytown is located along the eastern bank of the Hudson River, about 25 miles north of midtown Manhattan.

For over 30 years, the Westchester County community has helped us grow. Because of that, we've been able to build 1.7 million square feet of state-of-the-art laboratory resources that employ more than 4,000 passionate employees across the region who all have the same mission—advancing the delivery of life-saving medicines for the growing number of patients in need.



Put the world at your doorstep. With our region's reliable interconnected roadways, bus stations, rail lines and leading regional airport, traveling around the world is as convenient as traveling around our county.



Feel safe and secure. Our highly ranked, safe neighborhoods are home to some of the nation's leading healthcare systems, so you can ensure you have the resources you need—around the block.



Set up success. Westchester's strong school districts, top graduation rates and several colleges and universities provide opportunity for the success of you and your family.



Enjoy your weekdays and your weekends. Westchester has an abundance of restaurants, performing-arts venues, sports centers, special events, and night life that make it easy to fill your weekend but difficult to choose how.

**REGENERON**  
SCIENCE TO MEDICINE®

*Create The Future  
You Believe In*

**IF YOU HAVE QUESTIONS,  
PLEASE CONTACT:**

**Bailie Saltzman**  
HR Contact  
Sr Talent Acquisition Specialist  
[pharmdbp@regeneron.com](mailto:pharmdbp@regeneron.com)